Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Candiolo – page 33

987 clinical trials in Candiolo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Candiolo at a glance
987
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

987 trials in Candiolo

Open in trial search

Study on Palonosetron and Netupitant for Preventing Nausea in Endometrial Cancer Patients Undergoing Taxane-Platinum Chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Fondazione IRCCS Istituto Nazionale Dei Tumori

Study on Lasofoxifene, Fulvestrant, and Abemaciclib for Advanced Breast Cancer in Women and Men with ESR1 Mutation

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Abemaciclib
  • Sponsor:Leonabio Inc.

Lymphangioma

Recruiting

Study on Alpelisib for Treating Lymphatic Malformations in Patients with PIK3CA Mutation

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Novartis Pharma AG

Study on Early Treatment Intensification for Acute Myeloid Leukemia with FLT3 Mutation Using Cytarabine, Midostaurin, and Daunorubicin Hydrochloride for Patients with Low Chemosensitivity

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Fondazione G.I.M.Em.A Franco Mandelli Ets

Study on Long-term Safety and Efficacy of Efgartigimod PH20 SC in Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efgartigimod Alfa
  • Sponsor:Argenx

Study on Long-Term Safety and Effects of Marstacimab for Patients with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Marstacimab
  • Sponsor:Pfizer Inc.

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Study on Switching from Tacrolimus or Ciclosporin to Belatacept for Adolescents with Kidney Transplants

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Belatacept
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Prostate cancer

Recruiting

Study of Apalutamide and Radiation Therapy for Patients with Low Burden Metastatic Hormone Sensitive Prostate Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Apalutamide
  • Sponsor:Fondazione Radioterapia Oncologica Onlus

Study on Vericiguat for Children with Heart Failure Due to Left Ventricular Systolic Dysfunction

Investigational
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Vericiguat
  • Sponsor:Merck Sharp & Dohme LLC

Study of ONC201 for Patients with Newly Diagnosed H3 K27M-mutant Diffuse Glioma After Radiotherapy

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Dordaviprone
  • Sponsor:Chimerix Inc.

Study on Marstacimab for Children with Severe Hemophilia A or B, With or Without Inhibitors

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Marstacimab
  • Sponsor:Pfizer Inc.

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Candiolo

What the registry says about research in the country

01 Hematologic Malignancies

Advanced research focusing on blood cancers including innovative treatments for myelodysplastic syndromes, follicular lymphoma, and chronic myelomonocytic leukemia. Studies evaluate novel drug combinations and maintenance therapies to improve patient outcomes.

  • Multiple Myeloma Treatment Optimization
  • Lymphoma Therapy Innovations
  • Leukemia Treatment Strategies

Trials investigate targeted therapies and immunotherapy approaches for better disease management.

02 Solid Tumors

Comprehensive research on lung cancer, breast cancer, and colorectal cancer. Studies explore combination therapies involving immunotherapy, targeted agents, and conventional treatments to enhance treatment efficacy.

  • Advanced NSCLC Treatments
  • Metastatic Disease Management
  • Novel Drug Combinations

Focus on personalized medicine approaches and biomarker-driven treatment selection.

03 Rare Cancers

Dedicated research into sarcomas, head and neck cancers, and other rare malignancies. Studies evaluate novel therapeutic approaches including immunotherapy combinations and targeted treatments.

  • Osteosarcoma Treatments
  • Soft Tissue Sarcoma Therapy
  • Innovative Treatment Protocols

Emphasis on developing effective treatments for cancers with limited therapeutic options.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.